Implementing evidence-based management of dyslipidaemia is a challenge worldwide. To understand physician beliefs and behaviour and identify uncertainties in dyslipidaemia management across four world regions. Web-based survey of 1758 physicians in Japan, Germany, Colombia and the Philippines who were selected randomly from existing databases. Key inclusion criteria were 1) for cardiologists and diabetes/endocrinology specialists: ≥50 dyslipidaemia patients examined in the last month; 2) for specialists in neurology/neurosurgery/stroke medicine: ≥50 dyslipidaemia patients and ≥ 20 patients with a history of ischaemic stroke examined in the last month; and 3) for specialists in nephrology and general medicine: based at centres with ≥20 beds and ≥ 50 dyslipidaemia patients examined in the last month. The self-report survey covered dyslipidaemia management, target low-density lipoprotein cholesterol (LDL-C) levels in different patient groups, and statin safety. All physicians gave voluntary consent and all data were anonymised. Analysis was solely descriptive. The survey highlighted key areas of uncertainty in dyslipidaemia management in the four countries. These related to LDL-C targets in different patient groups, the safety of low LDL-C levels, the safety of statins, especially for effects on cognitive, renal and hepatic function and for haemorrhagic stroke risk, and lipid management strategies in patients with chronic kidney disease, including those with concomitant hypertriglyceridaemia. This survey of physicians in Japan, Germany, Colombia and the Philippines has identified key gaps in knowledge about dyslipidaemia management. These relate to the safety of low LDL-C levels, the safety of statins, and lipid management of chronic kidney disease. The findings from this survey highlight the need for further education to improve the implementation of guideline recommendations for dyslipidaemia management.

中文翻译：

---

日本，德国，哥伦比亚和菲律宾在血脂异常管理方面的信念和实践方面的差距：基于网络的医生调查得出的见解。

在全球范围内，实施基于证据的血脂异常管理是一项挑战。了解医师的信念和行为，并确定世界四个地区血脂异常管理的不确定性。基于网络的日本，德国，哥伦比亚和菲律宾的1758名医生的调查，这些医生是从现有数据库中随机选择的。关键纳入标准为：1）心脏病专家和糖尿病/内分泌专家：上个月检查的≥50名血脂异常患者；2）对于神经内科/神经外科/中风医学专家：最近一个月检查的≥50名血脂异常患者和≥20名有缺血性中风病史的患者；3）肾脏科和普通科专家：在上个月接受检查的床位≥20且血脂异常≥50的中心。自我报告调查涵盖了血脂异常的治疗，不同患者组的目标低密度脂蛋白胆固醇（LDL-C）水平以及他汀类安全性。所有医生均自愿同意，所有数据均匿名。分析仅是描述性的。该调查突出了这四个国家血脂异常管理的主要不确定性领域。这些与不同患者群中的LDL-C指标，低LDL-C水平的安全性，他汀类药物的安全性有关，尤其是对于慢性患者的认知，肾和肝功能影响以及出血性中风风险以及脂质管理策略肾脏疾病，包括高甘油三酸酯血症。这项对日本，德国，哥伦比亚和菲律宾的医生的调查确定了血脂异常管理知识方面的主要差距。这些与低LDL-C水平的安全性，他汀类药物的安全性以及慢性肾脏疾病的脂质管理有关。这项调查的结果表明，有必要进行进一步的教育以改善血脂异常管理指南的实施。